Alkermes (ALKS) Operating Expenses (2010 - 2026)
Alkermes' (ALKS) quarterly Operating Expenses came in at $441.2 million in Q1 2026, up 50.72% year-on-year from $292.7 million in Q1 2025, and up 4934.7% on a QoQ basis from $8.8 million in Q4 2025.
Alkermes (ALKS) Operating Expenses (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Operating Expenses data on file, last reported at $441.2 million in Q1 2026.
- On a quarterly basis, Operating Expenses rose 50.72% year-over-year to $441.2 million in Q1 2026; TTM through Mar 2026 was $760.9 million, a 32.22% decrease from a year earlier, with the FY2025 full-year figure at $12.3 million, down 98.92% from the prior year.
- Operating Expenses for Q1 2026 stood at $441.2 million, up from $8.8 million in the prior quarter.
- Over the last five years, Operating Expenses for ALKS reached as high as $441.2 million in Q1 2026 and fell as low as $5.4 million in Q1 2024.
- Historically, Operating Expenses has averaged $250.4 million across 5 years, with a median of $292.7 million in 2025.
- Across the five-year window, Operating Expenses sank 98.18% in 2024 and jumped 5300.7% in 2025, its largest moves.
- Year by year, Operating Expenses stood at $189.1 million in 2022, then soared by 70.74% to $322.8 million in 2023, then declined by 17.21% to $267.3 million in 2024, then slumped by 96.72% to $8.8 million in 2025, then soared by 4934.7% to $441.2 million in 2026.
- Per Business Quant data, the three most recent Operating Expenses figures were $441.2 million in Q1 2026, $8.8 million in Q4 2025, and $305.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 1.00 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 788.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 12.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 455.70 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.24 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 621.10 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 494.00 Mn |
| 10 | Alkermes | 8.78 Bn | 8.27 Bn | 331.33 Mn | 441.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 441.19 Mn |
| Dec 31, 2025 | 8.76 Mn |
| Sep 30, 2025 | 305.10 Mn |
| Jun 30, 2025 | 5.88 Mn |
| Mar 31, 2025 | 292.72 Mn |
| Dec 31, 2024 | 267.30 Mn |
| Sep 30, 2024 | 273.39 Mn |
| Jun 30, 2024 | 289.25 Mn |
| Mar 31, 2024 | 5.42 Mn |
| Dec 31, 2023 | 322.84 Mn |
| Sep 30, 2023 | 291.74 Mn |
| Jun 30, 2023 | 336.13 Mn |
| Mar 31, 2023 | 298.57 Mn |
| Dec 31, 2022 | 189.08 Mn |
| Sep 30, 2022 | 313.00 Mn |
| Jun 30, 2022 | 310.68 Mn |
| Mar 31, 2022 | 305.13 Mn |
| Dec 31, 2021 | 195.05 Mn |
| Sep 30, 2021 | 313.80 Mn |
| Jun 30, 2021 | 299.30 Mn |